RegisterLogin

BMS-309403

CAT: 0804-HY-101903-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-101903-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of [1][2][3].
CAS Number
[300657-03-8]
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
FABP
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Metabolic Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/BMS-309403.html
Purity
99.93
Solubility
DMSO : 175 mg/mL (ultrasonic)
Smiles
O=C(O)COC1=CC(C2=CC=CC=C2N3N=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=C3CC)=CC=C1
Molecular Formula
C31H26N2O3
Molecular Weight
474.55
Precautions
H302, H312, H332
References & Citations
[1]Sulsky R, et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP) . Bioorg Med Chem Lett. 2007 Jun 15;17 (12) :3511-5.|[2]Lin W, et al. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS One. 2012;7 (8) :e44570.|[3]Lee MY, et al. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 2011 Apr;162 (7) :1564-76.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Am J Cancer Res. 2019 Oct 1;9 (10) :2140-2155.|Antioxidants (Basel) . 2022 Dec 29;12 (1) :74.|Biochem Pharmacol. 2025 Jul 11:241:117152.|BMC Chem. 2025 Sep 30;19 (1) :270.|Bone Res. 2022 Jun 22;10 (1) :45.|Br J Nutr. 2022 Jan 14;127 (1) :3-11.|Cancer Lett. 2023 Oct 28:575:216403.|Cell Death Dis. 2019 May 16;10 (6) :382. |Cell Mol Life Sci. 2024 Feb 10;81 (1) :83.|Comp Biochem Physiol B Biochem Mol Biol. 2022 Apr-May:259:110715.|Food Chem Toxicol. 2025 Apr 2:115428.|Free Radic Biol Med. 2022 Aug 20:189:42-57.|Indian J Dermatol Venereol Leprol. 2025 Jul 4:1-13.|Int Immunopharmacol. 2023 Sep 2;124 (Pt A) :110859.|Int J Biol Sci. 2021 Oct 11;17 (15) :4207-4222.|Iran J Basic Med Sci. 2022 Oct;25 (10) :1260-1266.|J Med Chem. 2025 Jun 12;68 (11) :11127-11148.|J Proteomics. 2020 Feb 10;212:103570.|Mol Neurobiol. 2025 Nov 21;63 (1) :130.|Neurosci Lett. 2025 Mar 28:853:138199.|Parasitol Res. 2019 Jun;118 (6) :1919-1926. |EMBO Mol Med. 2025 Aug 4.

Related Products

CatalogName
HY-120620-01BMS-195270
HY-139562BMS-986318
HY-108432BMS-741672
HY-145373BMS-986143
HY-14225BMS-764459
HY-117074BMS-247243
HY-120623-01BMS-284640
HY-P2021BMS 180742
HY-19667BMS-561392
HY-120625BMS-358233

Alternative Products

CatalogName
GW9859-25mgBMS-309403
B7794-10BMS 309403
MBS5806025BMS-309403 sodium
TBI4762-5MGBMS-309403, FABP4 inhibitor
443059-01BMS 309403 discontinued. See 254789
MBS386661-01BMS-806 (BMS 378806)
A11201-1BMS-806 (BMS 378806) 1mg
A11201-2BMS-806 (BMS 378806) 2mg
A11201-500BMS-806 (BMS 378806) 500mg

Popular Products